Paxlovid’s role in treating COVID-19 is not ending — it is evolving, according to the results of two national trials ...
In this real‑world multicenter study (Wenzhou, China), 113 chronic hepatitis C patients received colbopasvir (60 mg) + sofosbuvir (400 mg) daily for 12 weeks. Overall SVR12 was 99.1% (112/113). SVR12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results